Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVCN110101a
- Development stage
- Preclinical
- Lead developer
- Avicanna
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
AVCN110101a is a preclinical-stage botanical cannabinoid formulation being developed by Avicanna. It utilizes Avicanna's proprietary QUIX self-emulsifying drug delivery system (SEDDS) technology, which is designed to address challenges associated with cannabinoid delivery, such as poor water solubility, low bioavailability, and delayed onset of action. The formulation is intended for oral administration, with specific therapeutic indications yet to be determined.
- Other names
- Quix
Beyond the preview
Go deeper on AVCN110101a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVCN110101a.